Structure Therapeutics (GPCR) Set to Announce Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) is projected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.3250) per share and revenue of $50.00 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts expect Structure Therapeutics to post ($1.87) EPS for the current fiscal year and ($2.09) EPS for the next fiscal year.

Structure Therapeutics Stock Performance

NASDAQ:GPCR traded up $0.61 during trading hours on Tuesday, reaching $21.08. The stock had a trading volume of 63,860 shares, compared to its average volume of 960,380. The stock has a market cap of $1.47 billion, a P/E ratio of -21.08 and a beta of -1.12. The stock has a 50 day simple moving average of $32.86 and a 200 day simple moving average of $49.16. Structure Therapeutics has a 12-month low of $20.42 and a 12-month high of $94.90.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Citizens Jmp reiterated a “market outperform” rating and set a $110.00 price target on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Weiss Ratings cut Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a report on Friday, August 7th. Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.